Accenture/BioQ: promising alliance announced

Published By Datamonitor

Ache: Brazilian domestic player to step up its game

Ache, the Brazilian branded generics specialist, has announced its intention to pursue an initial public offering in order to raise capital and remain competitive. The move reflects the growing interest in Brazil's burgeoning pharmaceutical market, and is essential if Ache is to compete with the considerable growth in both domestic and international players in the country.

Published By Datamonitor

Acomplia's EU suspension dispels illusion of blockbuster future

The EMEA has suspended Acomplia due to the risk of serious psychiatric disorders. The anti-obesity agent had been promised a sure success by numerous analysts, as it addressed indications beyond obesity. However, Acomplia failed to win approval in the US, and just two years after the EU approval its sales have been completely halted, leaving the potentially vast anti-obesity market bare again.

Published By Datamonitor

Acorda/Biogen Idec: pricing will determine success of symptomatic MS therapy

The FDA has approved Acorda's Ampyra for the symptomatic treatment of multiple sclerosis, making it the first therapeutic option approved to address walking impairments experienced by patients with the disease. However, despite favorable efficacy data, prescriptions are likely to be limited by price concerns and the risk of seizures.

Published By Datamonitor

ACR 2009: Benlysta outshines disappointing rheumatoid arthritis data

Datamonitor recently attended this year's American College of Rheumatology Annual Conference in Philadelphia. No ground-breaking data for rheumatoid arthritis therapies were presented; instead, systemic lupus erythematosus stole the limelight. Human Genome Sciences' Benlysta in particular generated a stir, being the first drug in this indication to generate positive data at Phase III.

Published By Datamonitor

Actelion/GlaxoSmithKline: future of innovative orexin drug class in doubt

Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.

Published By Datamonitor

Actelion: FDA endorses first drug

Published By Datamonitor

Actelion: Tracleer approved for pulmonary hypertension

As the first approved oral medication for PAH, the new drug is likely to be popular among treating physicians and enjoy a rapid uptake. However, while Tracleer may improve patients' symptoms, it is a far cry from a cure for PAH, leaving an effective treatment for PAH a major unmet need in the cardiovascular therapeutics market.

Published By Datamonitor

Actos suspension could shake up a market already in transition

Takeda's antidiabetic drug Actos has been suspended in France and Germany following study findings which show that it is associated with an increased risk of bladder cancer. Will other countries follow and how will this impact the oral antidiabetics market?

Published By Datamonitor

Acute coronary syndrome: GRAVITAS gives AstraZeneca and Eli Lilly a mandate, but who will cash in?

Results from the GRAVITAS trial suggest that there is no benefit in treating low-risk post-percutaneous coronary intervention patients with high residual platelet activity with a double dose of clopidogrel. The results are not definitive, however: it was a relatively small trial performed in relatively low-risk patients, and may have been insufficiently powered.

Published By Datamonitor